| pubmed-article:8381188 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8381188 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8381188 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:8381188 | lifeskim:mentions | umls-concept:C1516238 | lld:lifeskim |
| pubmed-article:8381188 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:8381188 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:8381188 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:8381188 | lifeskim:mentions | umls-concept:C0205231 | lld:lifeskim |
| pubmed-article:8381188 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8381188 | pubmed:dateCreated | 1993-3-1 | lld:pubmed |
| pubmed-article:8381188 | pubmed:abstractText | Chemotherapy may induce overall (complete plus partial) response rates of more than 50% and complete response rates up to 25% in extensive small-cell lung cancer (stage IIIB or IV), but survival is generally limited to 8-12 months. Interleukin-2 (IL-2) has demonstrated activity against this disease in vitro and has produced regression in melanoma and renal cell carcinoma. | lld:pubmed |
| pubmed-article:8381188 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8381188 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8381188 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381188 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8381188 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8381188 | pubmed:issn | 0027-8874 | lld:pubmed |
| pubmed-article:8381188 | pubmed:author | pubmed-author:GreenM RMR | lld:pubmed |
| pubmed-article:8381188 | pubmed:author | pubmed-author:OzerHH | lld:pubmed |
| pubmed-article:8381188 | pubmed:author | pubmed-author:PerryM CMC | lld:pubmed |
| pubmed-article:8381188 | pubmed:author | pubmed-author:KreismanHH | lld:pubmed |
| pubmed-article:8381188 | pubmed:author | pubmed-author:HerndonJJ | lld:pubmed |
| pubmed-article:8381188 | pubmed:author | pubmed-author:EllertonJJ | lld:pubmed |
| pubmed-article:8381188 | pubmed:author | pubmed-author:ClamonGG | lld:pubmed |
| pubmed-article:8381188 | pubmed:author | pubmed-author:MaherTT | lld:pubmed |
| pubmed-article:8381188 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8381188 | pubmed:day | 17 | lld:pubmed |
| pubmed-article:8381188 | pubmed:volume | 85 | lld:pubmed |
| pubmed-article:8381188 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8381188 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8381188 | pubmed:pagination | 316-20 | lld:pubmed |
| pubmed-article:8381188 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:meshHeading | pubmed-meshheading:8381188-... | lld:pubmed |
| pubmed-article:8381188 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8381188 | pubmed:articleTitle | Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. | lld:pubmed |
| pubmed-article:8381188 | pubmed:affiliation | Department of Internal Medicine, University of Iowa College of Medicine, Iowa City. | lld:pubmed |
| pubmed-article:8381188 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8381188 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8381188 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8381188 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8381188 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8381188 | lld:pubmed |
